CORONANSECORONA Remedies LimitedMediumNeutral
Announced Mon, 11 May · 18:11 IST

CORONA Remedies Limited has informed the Exchange about change in ManagementRe-appointment of M/s. Manish B. Analkat, as Cost Auditor of the Company for the Financial Year 2026-27

Management Changes View source PDF

CORONA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
-2.8%1-day move
₹1765.00
prior close
₹1776.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.9+1.2+1.4+1.3-2.8+1.3-0.6+3.1+0.7-2.5-3.3-1.8+16.7
Up moveDown movePending
AI summary

CORONA Remedies Limited has re-appointed M/s. Manish B. Analkat as Cost Auditor for the financial year 2026-27. Cost auditors are appointed to examine and verify the company's cost accounting records as mandated under the Companies Act. This is a routine annual re-appointment, indicating continuity in the company's compliance framework. The filing falls under the 'Change in Management' category on NSE due to auditor appointments being classified under management changes.

Likely market impact

This is a routine governance action with no material impact on shareholders or stock price. The re-appointment of an existing cost auditor suggests smooth ongoing operations and compliance.